These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Biosimilars for insulin: a cost-saving alternative? McCall C Lancet; 2018 Aug; 392(10146):463-464. PubMed ID: 30129449 [No Abstract] [Full Text] [Related]
4. The impact of biosimilar insulins on the diabetes landscape. White J; Wagner A; Patel H J Manag Care Spec Pharm; 2022 Jan; 28(1):91-98. PubMed ID: 34726499 [TBL] [Abstract][Full Text] [Related]
5. Role of Devices in Insulin Delivery. Meneghini LF; McNulty JN Diabetes Technol Ther; 2017 Feb; 19(2):76-78. PubMed ID: 28118052 [No Abstract] [Full Text] [Related]
6. Fate of cost-saving biosimilar drugs may hinge on naming policy. Johnson SR Mod Healthc; 2016 Aug; 45(27):7, 9. PubMed ID: 30387953 [No Abstract] [Full Text] [Related]
7. Examining the Causes and Consequences of Increasing Insulin Costs With Prospective Interventions. Dawkins M; Menon T; Myers AK Am J Ther; 2020; 27(1):e115-e120. PubMed ID: 31703009 [No Abstract] [Full Text] [Related]
8. Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database. Kim J; Ha D; Song I; Park H; Lee SW; Lee EK; Shin JY Int J Rheum Dis; 2018 Jun; 21(6):1227-1236. PubMed ID: 29667324 [TBL] [Abstract][Full Text] [Related]
9. Biosimilar drugs: Measures to promote their use. Guiu Segura JM; Gilabert Perramon A Med Clin (Barc); 2020 Feb; 154(4):148. PubMed ID: 30981435 [No Abstract] [Full Text] [Related]
10. Addressing Insulin Access and Affordability: An Endocrine Society Position Statement. Endocrine Society J Clin Endocrinol Metab; 2021 Mar; 106(4):935-941. PubMed ID: 33433590 [TBL] [Abstract][Full Text] [Related]
11. Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA. Bennett CL; Sartor OA; Armitage JO; Kantarjian H Lancet Oncol; 2017 Jan; 18(1):22-23. PubMed ID: 28049571 [No Abstract] [Full Text] [Related]
12. Friction in the Path to Use of Biosimilar Drugs. Frank RG N Engl J Med; 2018 Mar; 378(9):791-793. PubMed ID: 29490182 [No Abstract] [Full Text] [Related]
14. Examining the reality of what insulin costs do to patients. Gabbay RA Am J Manag Care; 2019 Sep; 25(10 Spec No.):. PubMed ID: 31860236 [No Abstract] [Full Text] [Related]
15. [Biosimilar drugs – just as good, and much cheaper]. Goll GL Tidsskr Nor Laegeforen; 2019 Mar; 139(6):. PubMed ID: 30917643 [No Abstract] [Full Text] [Related]
16. The rise of biosimilars in cancer care. Roe H Br J Nurs; 2015 Feb 26-Mar 11; 24(4):S28-9. PubMed ID: 25723369 [No Abstract] [Full Text] [Related]
17. Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018. Hernandez I; Good CB; Shrank WH; Gellad WF JAMA; 2019 Apr; 321(16):1627-1629. PubMed ID: 30907933 [TBL] [Abstract][Full Text] [Related]
18. For young adults with type 1 diabetes, insulin costs can mean chasing benefits, not dreams. Rosenberg J Am J Manag Care; 2019 Sep; 25(10 Spec No.):. PubMed ID: 31860239 [No Abstract] [Full Text] [Related]
19. The role of biosimilar manufacturers in improving access to insulin globally. Perrin C; Ewen M; Beran D Lancet Diabetes Endocrinol; 2017 Aug; 5(8):578. PubMed ID: 28629907 [No Abstract] [Full Text] [Related]
20. Bullying biosimilars: cheaper drugs stymied in USA. The Lancet Gastroenterology Hepatology Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):371. PubMed ID: 29739669 [No Abstract] [Full Text] [Related] [Next] [New Search]